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Abstract: The effect of SLN incorporation on transdermal delivery and in vitro antiherpetic 
activity of Artemisia arborescens essential oil was investigated. Two different SLN formulations 
were prepared using the hot – pressure homogenization technique, Compritol 888 ATO as lipid, 
and Poloxamer 188 and Miranol Ultra C32 as surfactants. Formulations were examined for their 
stability for two years by monitoring average size distribution and zeta potential values. The 
antiviral activity of free and SLN incorporated essential oil was tested in vitro against Herpes 
Simplex Virus-1 (HSV-1) by a quantitative tetrazolium-based colorimetric method (MTT), 
while the effects of essential oil incorporation into SLN on both the permeation through and 
the accumulation into the skin strata was investigated by using in vitro diffusion experiments 
through newborn pig skin and an almond oil Artemisia essential oil solution as a control.
Results showed that both SLN formulations were able to entrap the essential oil in high yields 
and that the mean particle size increased only slightly after two years of storage, indicating a 
high physical stability. In vitro antiviral assays showed that SLN incorporation did not affect 
the essential oil antiherpetic activity. The in vitro skin permeation experiments demonstrated the 
capability of SLN of greatly improving the oil accumulation into the skin, while oil permeation 
occurred only when the oil was delivered from the control solution.
Keywords: SLN, solid lipid nanoparticles, HSV-1 virus, antiviral agent, Artemisia arborescens 
essential oil
Introduction
Herpes simplex virus (HSV) is one of the most common viral diseases in humans. 
HSV exists as two types, herpes simplex virus 1 (HSV-1) and herpes simplex virus 
2 (HSV-2) which have been distinguished by clinical manifestations, biological and 
serological criteria. A characteristic property of herpes viruses is their ability to 
establish and maintain latent infections that can be frequently reactivated by several 
different stimuli such as stress, ultraviolet light, hormones, transient hyperthermia, 
and immunosuppression. Infections of these viruses can cause a wide range of signs 
and symptoms varying from mucocutaneous lesions to life-threatening encephalitis 
(Whitley and Lakeman 1995; Simmons 2002).
Several drugs have proven to be useful in the treatment of many speciﬁ  c infections, 
but viral strains resistant to these drugs have been increasingly identiﬁ  ed and several 
cases of toxicity have been encountered, particularly in immunocompromised patients 
(Nugier et al 1992). According to the type and severity of the infection, antiviral 
agents may be administered via several routes: orally for the treatment of primary 
oral or genital infections, parenterally for serious infections such as neonatal herpes 
and herpes infections of the central nervous system, in drops for ocular herpetic infec-
tions and topically on lips and mucosae for mild recurrent orolabial lesions (Brady 
and Berstein 2003).International Journal of Nanomedicine 2007:2(3) 420
Lai et al
In order to ﬁ  nd less toxic antiviral agents much research 
has focused on plant products. In a previous paper we 
demonstrated the in vitro antiviral activity of the essential oil 
extracted from Artemisia arborescens L. Our results showed 
that the incorporation of this essential oil in multilamellar 
liposomes greatly improved its activity against intracellular 
HSV-1 (Sinico et al 2005).
Introduced at the beginning of the 1990s, solid lipid 
nanoparticles (SLN) have been intensively investigated 
for parenteral, peroral (Müller et al 1995; Lai and Wissing 
2003) and ocular delivery. Furthermore, because of their 
ability to enhance the penetration of drugs into the skin 
SLN are considered a promising drug carrier for topical 
application (Mehnert and Mader 2001). In particular, SLN 
are well suited for use in damaged or inﬂ  amed skin because 
the lipids used for their preparation are often non toxic and 
non irritative (Wissing and Müller 2001; Wissing and Mül-
ler 2002; Wissing and Müller 2003). The aim of our study 
was the incorporation of Artemisia arborescens L essential 
oil into SLN as topical delivery systems against Herpes 
simplex virus 1. The antiviral activity of free and SLN incor-
porated essential oil was tested in vitro against HSV-1 by a 
quantitative tetrazolium-based colorimetric method (MTT), 
while the effects of Artemisia arborescens L essential oil 
incorporation into SLN on both the permeation through 
the skin and the accumulation into the skin strata was 
investigated by using in vitro diffusion experiments through 
newborn pig skin.
Experimental
Materials
Compritol 888 ATO® which was a gift from Gattefossé 
(Milan, Italy) is declared as glyceryl behenate with a melting 
point of 72 ºC. It is a mixture of 12%–18% mono-, 52%–54% 
di- and 28%–32% triglycerides. The fatty acid fraction con-
sists of >87% behenic acid (docosan acid). The surfactant 
Pluronic F68® (Poloxamer 188) was obtained from BASF 
AG (Ludwigshafen, Germany), Miranol Ultra C32® (sodium 
cocoamphoacetate) was a gift from Rhodia Gerozzano S.p.A. 
(Ospiate Bollate, Italy). Camphor, a + β-thujone and Nonidet 
P40 were from Fluka (Milan, Italy). 3-(4, 5-dimethylthiazol-
2-yl)–2, 5-diphenyl tetrazolium bromide (MTT) was Sigma 
(Milan, Italy).
Virus and cells
African green monkey kidney cells (Vero) were obtained 
from the Istituto Zooprofilattico Sperimentale della 
Lombardia e dell’Emilia (Brescia, Italy). Cells were grown 
in RPMI 1640 (Gibco Life Technologies, Rockville, MD, 
USA) supplemented with 10% foetal bovine serum (FBS, 
Gibco) and penicillin, streptomycin and amphotericin B 
(100 U/ml, 100 and 2.5 μg/ml, respectively). The strain 
of Herpes Simplex virus type 1 (HSV-1 strain F) was ob-
tained from the American type culture collection (ATCC), 
Rockville, MD, USA, and was propagated in Vero cells. 
Virus titer was determined by plaque assay in Vero cells and 
stored at –70 °C until used.
Preparation and characterization 
of essential oil
The aerial parts of Artemisia arborescens were collected 
from the countryside around Usellus, Sardinia, Italy, during 
full blossom. Plants were identiﬁ  ed and voucher specimens 
deposited in the Herbarium of the Institute of Botany and 
Botanical Garden, University of Cagliari, Italy. 5 Kg of fresh 
aerial parts were distilled in a steam apparatus (Albrigi Luigi 
S.r.l. Verona, Italy) with an aqueous phase recycling system 
for 3 h. Brieﬂ  y the system is divided into three components: 
a 250 liter stainless steel cylinder which holds the plant 
material and water; a condenser, which the oil-steam mixture 
travels into to cool and condense into an oil-water mixture; a 
separator, which separates the essential oils from the water. 
The essential oil was dried over anhydrous sodium sulphate 
and stored at 4 °C. The quali-quantitative analysis of the 
essential oil was carried out by gas chromatography-ion 
trap mass spectrometry (GC/ITMS). A Varian CP 3800 gas 
chromatograph (Varian, Inc., Palo Alto, CA, USA) coupled 
with a Saturn 2000 ITMS detector, a Varian CP 7800 
autosampler, a split-splitless injector, and a MS ChemStation, 
was used. The column was a fused silica capillary DB-5MS 
(5% phenylmethylpolysyloxane, 30 m × 0.25 mm; ﬁ  lm 
thickness 0.25 μm) (J and W Scientiﬁ  c Fisons, Folsom, CA). 
The injector and interface were at 150 °C and 280 °C, respec-
tively. The oven temperature was programmed as follows: 
from 60 °C to 180 °C (3 °C/min), and isothermally held for 
15 min. Helium was the carrier gas at 1 ml/min; the sample 
(1 μl) was injected in the split mode (1:20). MS conditions 
were as follows: ionization mode EI from 50–450 amu. 
The oil compounds were identiﬁ  ed by comparison of their 
relative retention times with those of authentic samples or 
by comparison of their retention index (RI) relative to the 
series of n-hydrocarbons, and computer matching against 
commercial library (Adams 1995, Nist Mass Spectral Search 
Program 1999) and homemade library mass spectra made 
up from pure substances and component of known oils and 
MS literature data.International Journal of Nanomedicine 2007:2(3) 421
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The oil content was also assayed by HPLC at several 
wavelengths (209, 245 and 284 nm), using a Waters 2690 
liquid chromatograph, equipped with a Photodiode Array 
detector 996 (Waters Corp, Milford, MA). The mobile 
phases were methanol and water. Separations were performed 
using 75% methanol and 25% water as eluent at a ﬂ  ow 
rate of 1.0 ml/min. The column was an Xbridge C18 5 μm 
(4.6 × 150 mm, Waters). Appropriate standard methanolic 
solutions of camphor and α + β-thujon were prepared 
and tested. All experiments were carried out in triplicate. 
Because of complexity of the essential oil composition, the 
permeation study was carried out by quantifying the most 
abundant essential oil components. To this purpose camphor, 
β-thujon and chamazulene were used as “lead” components 
as previously reported (Sinico et al 2005). In particular, 
the camphor was determined at 284 nm and the β-thujon at 
209 nm. Retention times for camphor and β-thujon were 
respectively 1.74 and 2.67.
SLN preparation and characterization
SLN were prepared as previously reported (Lai et al 2006). 
Brieﬂ  y, Artemisia arborescens L. essential oil was dissolved 
in the melted Compritol 888 ATO® at 75 ºC and the essential 
oil-loaded lipid dispersed in a hot aqueous surfactant solu-
tion. The mixtures were stirred with a T 25 Ultra Turrax 
(Janke und Kunkel GmbH and Co KG Staufen, Germany) for 
1 minute at 8000 rpm. The obtained pre-emulsion was then 
homogenized at high pressure (three cycles, 500 bar) using 
an Emulsiﬂ  ex C5 (Avestin Ottawa, Canada) thermostated at 
75 ºC (Müller and Lucks 1996). Details of SLN formulations 
are given in Table 1.
The SLN dispersions were puriﬁ  ed from non-incorporated 
Artemisia arborescens L. essential oil by gel chromatography 
on Sephadex G50. The encapsulation efﬁ  ciency was calcu-
lated using the following equation: [(T-S)/T] × 100. T is the 
total quantity of incorporated and non-incorporated essential 
oil in the SLN dispersion and S is the non-incorporated oil 
quantity separated with gel chromatography. Quantitative 
determination of incorporated essential oil was carried out 
spectrophotometrically using the HPLC method previously 
described after extraction and dilution with methanol for 
1 hour in an ultrasonic bath.
The average diameter (Z-AVE) and polydispersity index 
(PI) of SLN were determined by Dynamic Laser Light Scat-
tering (DLLS) using a (N4 Plus, Beckman Coulter) at 25 °C. 
The aqueous SLN dispersions were diluted with distilled 
water before analysis. Samples were scattered (633 nm) at 
an angle of 90°. Data were ﬁ  tted by the method of inverse 
"Laplace transformation" and CONTIN (Provencher 1982a, 
1982b). Each value is the average of ten measurements. The 
laser diffraction particle size analysis (LD) was performed by 
a Coulter LS 230 (Beckmann-Coulter Electronics, Germany). 
The LD data were evaluated using the volume distribution 
method to detect even few large particles. Characteriza-
tion parameters were the diameters LD 50, LD 90, LD 99, 
eg, a diameter LD 90 of 1 μm means that 90% of all particles 
have a diameter of 1 μm or less.
The particle charge was quantiﬁ  ed as zeta potential (ZP) 
using a Zetasizer 4 (Malvern Instr., UK) at 25 ºC. Measure-
ments were performed in bidistilled water adjusted with 
sodium chloride to a conductivity of 50 μS/cm. The pH 
values of the samples were always between 6.2 ± 0.9. Zeta 
potential was calculated from the electrophoretic mobility 
after Helmholtz-Smoluchowski equation (Smoluchowski 
1918).
Antiviral activity
The antiviral activity of free and SLN essential oil formu-
lations was evaluated against HSV-1. Vero cells 5 × 104 
in 50 μl of RPMI 1640 containing FBS 5% were seeded 
in 96 multiwell microtiter plates (Falcon 353872, Becton 
Dickinson, Franklin Lakes, NJ, USA). The essential oil 
or SLN formulations in 50 μl of RPMI 1640 were added 
to cells and infected with 20 μl of HSV-1 1 × 104 pfu/ml 
to obtain final concentrations of essential oil ranging be-
tween 100 and 0.39 μg/ml and a multiplicity of infection 
(MOI) of 0.02. Plates were incubated at 37 °C in 5% CO2 
incubator until the viral cytopathic effect (CPE) was ob-
served in untreated virus control wells (usually 48–72 h). 
The reduction of the viral CPE in the essential oil contain-
ing wells in relation to cell controls and virus controls was 
determined by a quantitative tetrazolium-based colorimet-
ric method. 30 μl of a 5 mg/ml solution of 3-(4, 5-dimeth-
ylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) 
in phosphate-buffered saline (PBS) were added to each 
well to obtain a final concentration of MTT of 1 mg/ml. 
Plates were incubated at 37 °C for 4 h and the formazan 
Table 1 Sample composition % (w/w)
Components   Formulations
 SLN  1  SLN  2
Compritol 888 ATO  9.0  9.0
Artemisia arborescens essential oil  1.0  1.0
Poloxamer 188  5.0  –
Miranol ultra C32  –  2.5
Water 85.0  87.5International Journal of Nanomedicine 2007:2(3) 422
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product was dissolved with a mix solution consisting of 
0.1 N HCl and 5% Nonidet P40 in isopropanol. After a 
few minutes at room temperature to ensure that all crystals 
were dissolved, the plates were read using an automatic 
plate reader (Sunrise Tecan, Grödig/Salzburg, Austria) 
at 570 nm test wavelength with a reference wavelength 
at 690 nm. The 50% inhibitory dose values (ID50), defined 
as the concentration of essential oil inhibiting 50% of the 
viral CPE, were calculated by regression analysis of the 
dose-response curves generated from the data (Denizot 
and Lang 1986).
Skin permeation studies
In vitro experiments were performed in the dark in triplicate 
using skin fragments excised from newborn pigs (Manconi 
et al 2006). The skin, previously frozen at –18 °C, was placed 
at + 4 °C 1 day before the experiments. The subcutaneous 
fat was carefully removed and the skin was cut into squares 
of 3 × 3 cm2 and randomized. One day before the start of the 
experiments the skin was pre-equilibrated in PBS solution 
at +25 °C. Circular pieces of this skin were ﬁ  xed on vertical 
Franz diffusion cells the receptor compartment of which 
(volume of 7 cm3 and an effective diffusion area of 0.636 cm2) 
were ﬁ  lled with a hydroalcoholic solution (ethanol:water 
40:60) which was constantly stirred with a small magnetic 
bar and thermostated at 37 °C. 100 μl of nonpuriﬁ  ed SLN 
formulation (0.1 mg/g) was applied to each of the skin pieces 
(Franz 1975). Because of the high lipophilicity of the essen-
tial oil components, an almond oil solution of the essential 
oil (0.1 mg/g) was also studied as a reference. Samples of the 
receiving solution were withdrawn after elapsed times of 1, 
2, 4, 6, and 8 h, replaced with an equal volume of hydroal-
coholic solution to ensure sink conditions and analyzed by 
HPLC to determine the amount of permeated essential oil. 
At the end of the experiment the skin surface was washed 3 
times with distilled water and then removed and dried with 
ﬁ  lter paper. The skin was crumbled with a scissors and soaked 
separately in 10 ml of ethanol for 24 h and then exposed to 
four sonication cycles of 30 min each in an ultrasound bath. 
Finally, the obtained solutions were concentrated and the 
essential oil content quantiﬁ  ed by HPLC.
Statistical analysis of data
Data analysis was carried out with the software package 
Microsoft Excel version 2001. Results were expressed as a 
mean ± standard deviation. Statistically signiﬁ  cant difference 
was determined using the analysis of variance (ANOVA) 
with p = 0.05 as a minimal level of signiﬁ  cance.
Results and discussion
A blue essential oil (EO) was obtained in good yield (0.8%) 
distilling the fresh aerial part of Artemisia arborescens in a 
steam apparatus with an aqueous phase recycling system for 
3 h. The oil slowly became green when stored in the presence 
of air and/or light. The analysis of EO conﬁ  rmed the literature 
data (Sacco et al 1983), that is that the oil composition is a 
complex mixture of organic compounds among which mono-
terpene ketones β-thujone and camphor represent more than 
50% of the essential oil. Chamazulene, which is responsible 
for the blue color of the volatile oil, is also one of the main 
components. In Table 2 the composition of the most abundant 
molecules of the essential oil is given.
Two different SLN formulations were prepared using 
the hot high-pressure homogenization technique, Compritol 
888 ATO as a lipid and Poloxamer 188 and Miranol Ultra 
C32 as surfactants.
One day after production, the SLN 1 had a size of 223 nm 
(0.243 PI) while the particle size of SLN 2 prepared using 
Miranol Ultra C32® as surfactant were 219 nm (0.301 PI) 
(Figure 1).
The mean particle size of the formulations increased only 
slightly after two years of storage, indicating a high physical 
stability of both SLN 1 and SLN 2 formulations (Figure 1). 
In particular, 2 years after production, SLN 1 and SLN 2 
formulations showed a mean size of 242 nm (0,285 PI) 
and 239 nm (0,321 PI). The PI values were always smaller 
than 0.350 indicating a fairly narrow size distribution of the 
particles.
The absence of particles in the micrometer range and 
aggregation was conﬁ  rmed by laser diffraction particle size 
analysis (LD). For both Artemisia arborescens L. essential 
oil loaded formulations SLN 1 and SLN 2, the obtained 
data showed a LD 99 smaller than 700 nm 2 years after 
production.
The use of negatively charged surfactant Miranol Ultra 
C32® leads to SLN formulation (SLN 2) characterized by 
high zeta potential. Generally it is accepted that ZP values of 
–30 mV and above characterize a stable formulation (Freitas 
Table 2 Main components of Artemisia arborescens essential oil 
as determined by GC and GC-ITMS
Component  Retention time Rt Area  %
α-Pinene 4.15  3.17
β-Thujone 13.32  23.97
Camphor 15.30  35.73
β-Carophyllene 19.67  3.32
Chamazulene 41.19  7.66International Journal of Nanomedicine 2007:2(3) 423
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and Müller 1998). The SLN 2 formulation possessed a high 
zeta potential at day 1 (–36.2 ± 0.5 mV) which did not change 
during the two investigational years (Table 3) indicating a 
high long-term stability of this formulation.
At day 1 the SLN 1 formulation prepared using the steric 
non-ionic surfactant Poloxamer 188 showed a ZP value 
of –15.6 ± 0.5 mV that decreased slightly during the inves-
tigational two years. The threshold of particle agglomeration 
is indicated at a zeta potential range between –20 mV and 
–11 mV. Energy input, such as high storage temperature, in 
a SLN dispersion with ZP values in this range or below can 
cause an increase in kinetic energy that could potentially 
promote the aggregation of particles (Freitas and Müller 
1998). However, for the steric stabilizer Poloxamer, it should 
be pointed out that its stabilizing efﬁ  ciency is not reﬂ  ected 
by the absolute ZP as demonstrated by the slightly increase 
of mean size during the investigated two years. The amount 
of entrapped and non-entrapped essential oil was deter-
mined at the wavelength of 284 nm using the HPLC method 
described in the experimental section after puriﬁ  cation by gel 
chromatography on Sephadex G50. Both SLN formulations 
showed a high capability of entrapping the essential oil. In 
particular the E% of SLN 1 and SLN 2 were 87% and 92% 
respectively. The high incorporation capability of Compritol 
888 ATO® SLN is achieved because of a high lipophilicity 
of the essential oil.
The antiviral activity of A. arborescens essential oil 
was determined by the reduction of viral CPE in Vero 
cells infected with HSV-1 using a MTT colorimetric 
method. For appropriate comparison, the antiviral activ-
ity of free and SLN loaded essential oil was determined 
and compared with that of empty SLN. Using the MTT 
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Figure 1 Mean particle size and polydispersity index (PI) of Artemisia arborescens essential oil loaded SLN 1 and SLN 2 formulations stored at 4 ºC for 1 day (D1), 60 days 
(D60) and 2 years after production.
Table 3 Zeta potential measurements (in mV) of Artemisia 
arborescens loaded SLN formulations in bidistilled water 
(50 μS/cm) stored at 4 ºC 1 day (D1), 60 days (D60) and 
2 years after production
Formulations  Zeta potential (mV)
SLN 1  D1  –15.6 ± 0.5
 D60  –12.1  ±  0.7
  2 years  –11.3 ± 0.8
  
  
SLN 2 D1  –36.2  ±  0.5
 D60  –39.0  ±  0.9
  2 years  –34.1 ± 1.1International Journal of Nanomedicine 2007:2(3) 424
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test the empty SLN did not show any detectable antiviral 
activity. Results are shown in Figure 2.
At the highest employed concentration (100 μg/ml) the 
essential oil induced a 36.20% of inhibition. No signiﬁ  cant 
differences in the antiviral activity were observed by 
loading the essential oil in SLN 1 (31.10%) and SLN 2 
(35.20%). Therefore, the encapsulation in lipid particles 
did not negatively affect the in vitro antiviral activity of 
the oil, although the high lipophilicity of the studied carrier 
systems.
In order to evaluate the effects of incorporation in 
SLN on the amount of Artemisia arborescens essential oil 
accumulated into the skin and the permeated quantities, 
we carried out in vitro permeation studies using the whole 
newborn pig skin and vertical Franz diffusion cells, as 
reported in the experimental section. During this study we 
compared the permeation data obtained from the two SLN 1 
and SLN 2 formulations with those obtained from an almond 
oil Artemisia arborescens essential oil solution. We used the 
almond oil solution as a reference because of the excellent 
penetrating, moisturing and restructuring properties of this 
oil, which is one of the most popular components of several 
dermatological and cosmetic products. Moreover, it is rich 
in oleic and linoleic essential fatty acids that may act as 
penetration enhancers without inducing detectable cellular 
damage. Therefore, we believe that this solution is a good 
control in the permeation study. Results of the permeation 
experiments are reported in Figure 3, where we list, for each 
of the vehicles, the amount of the essential oil accumulated 
into and delivered through the skin.
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Figure 2 Antiviral activity of A. arborescens essential oil as determined by the reduction of viral CPE. Vero cells were infected with HSV-1 (MOI 0.02) and incubated in the 
presence of serial dilutions of free essential oil (upward triangle), SLN 1 (solid square), SLN 2 (open square), in RPMI 1640 until the viral cytophatic effect was observed 
in untreated virus control wells and then processed as described.  The data represent the mean for six replicates of four separate experiments.
As can be seen from this ﬁ  gure, essential oil permeation 
occurred only when the oil was delivered from the control 
solution, while a signiﬁ  cant amount of essential oil released by 
SLN formulations was found into the skin strata. Such relevant 
differences can be explained as a consequence of the SLN 
behavior on the skin surface. As reported previously (Müller 
et al 2002), SLN seem to stick to the skin surface, forming 
an adhesive ﬁ  lm that increase skin hydration and promote 
penetration of active compounds as well as the carrier into 
the stratum corneum. Here, lipid particles form a depot from 
which the oil is slowly released. Because of its physico-chemi-
cal properties (high lipophilicity, solid state at physiological 
temperature) the carrier can not improve essential oil diffusion 
through the inner more hydrophilic skin layers.
On the contrary, the control oil solution promotes essential 
oil permeation probably by increasing skin hydration that in 
case favors almond oil components to diffuse through the 
skin together the essential oil components.
Therefore, results obtained during this work clearly 
indicate that SLN are a good carrier for the cutaneous delivery 
of the antiviral Artemisia arborescens essential oil. In fact, 
SLN have proved to incorporate the essential oil in good yield 
and to possess a long-term stability. Moreover, they greatly 
improve skin accumulation of the phytocomplex, avoiding 
its permeation through the skin. However, further in vivo 
studies are needed to conﬁ  rm these results.
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